📈 Stock
For a condition like retinitis pigmentosa (RP) - which involves over 150 genes - only one therapy currently exists, leaving 98% of patients without treatment options.
Onyx @ Union Square: Shankar Musunuri, CEO, Ocugen
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
Related
Nara Daubeney and Piers Daubeney, CEO and Co-Founder, Phaim | Onyx Live | JPM 2026
Millions of T1DM patients worldwide are on lifelong insulin and constant monitoring. But what if we could switch off the immune attack causing the disease?
Daniel Green, CEO, eSpraye | JPM 2026
If the disease is in the lungs, why deliver the drugs everywhere else?
Fabian Gerlinghaus, CEO, Cellares | Onyx Live | JPM 2026
The platform built to cut CAR-T manufacturing costs by ~50% is about to power its first patient dosing.
Stefan Scherer, CEO, 3T Biosciences | JPM 2026
Many biotechs are trying to perfect T cell targeting - but how many have the backing of Sean Parker and Thiel Capital?